Long-term survival after “drop metastases” of renal cell carcinoma to the bladder

Raviv, Stacy; Eggener, Scott E.; Williams, Dan H; Garnett, John E.; Pins, Michael; Smith, Norm D.

doi:10.1016/s0090-4295(02)01846-0

Cited by 21 publications

(20 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Metastatic spread to the bladder could be due to haematogenous spread via the general circulation or retrograde fashion, lymphatic spread and finally via direct intraluminal transit and seeding in the distal urothelium known as the, “drop method.”[8910] The management of these metastases include transurethral resection, partial or radical cystectomy and radiotherapy.…”

Section: Discussionmentioning

confidence: 99%

Rare synchronous metastases of renal cell carcinoma

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Rare synchronous metastases of renal cell carcinoma

et al. 2014

View full text Add to dashboard Cite

show abstract

“…More recent case reports have shown improved survival with resection of the metastatic lesion. Specifically, one case report described a patient with metachronous bladder metastasis who was alive and disease free at 6 years following transurethral resection [8]. Another case report described a patient with solitary synchronous bladder metastasis free of recurrence at 24 months [9].…”

Section: Discussionmentioning

confidence: 99%

Renal cell carcionoma with synchronous metastases to the bladder and lung

Jang¹,

Hwang²,

Hwang³

et al. 2013

CRCM

View full text Add to dashboard Cite

Renal cell carcinoma can metastasize to virtually any organ, yet synchronous metastasis to the bladder is extremely rare. A 77-year-old woman presented with gross hematuria. Abdominal and chest computed tomography showed a bilateral renal masses, bladder dome mass, and multiple lung metastasis. Transurethral resection of the bladder tumor and sonography guided renal biopsy were performed. Both pathology diagnoses were clear cell renal cell carcinoma. Targeted therapy using pazopanib was administered to the patient without surgical resection of primary tumors and metastatic lung lesions. Herein, we report the synchronous metastasis of renal cell carcinoma to the bladder and lung.

show abstract

“…Retrograde venous embolization of tumor cells and lymphatic extension are also proposed to explain this phenomenon. 2,5,11,14,15 The prognosis of patients with metastatic RCC to the urinary bladder is not well characterized, with scant literatures stating that the survival period varies from weeks to 6 years. 7,15 The reported histologic variants of RCC metastatic to urinary bladder have only been clear cell RCC and papillary RCC.…”

mentioning

confidence: 99%

“…2,5,11,14,15 The prognosis of patients with metastatic RCC to the urinary bladder is not well characterized, with scant literatures stating that the survival period varies from weeks to 6 years. 7,15 The reported histologic variants of RCC metastatic to urinary bladder have only been clear cell RCC and papillary RCC. 3,9,15 Herein, we report our experience of 11 cases of metastatic RCC to the urinary bladder, including 1 chromophobe RCC.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Metastatic Renal Cell Carcinoma to the Urinary Bladder

Zhang¹,

Cheuk

Epstein

2014

American Journal of Surgical Pathology

View full text Add to dashboard Cite

Metastatic renal cell carcinoma (RCC) to the urinary bladder is rarely seen. Herein, we report the histologic subtypes, immunohistochemical characteristics, and prognosis of 11 patients with metastatic RCC to the urinary bladder. The mean age at the time of diagnosis of metastatic RCC to the bladder was 66 years (range, 58 to 79 y). There were 9 male and 2 female patients. Four patients presented with hematuria, 2 with urinary retention/obstruction, and 1 with bladder calculi. Four patients were asymptomatic and presented for surveillance cystoscopy, wherein they were found to have bladder masses. Nine patients had prior histories of RCC. The remaining 2 patients presented with metastatic clear cell RCC to the bladder and were subsequently found to have renal masses. The average time between nephrectomy and metastasis to the bladder was 20.7 months (range, 0 to 87 mo). Of the 10 patients with radical/partial nephrectomy, 7 cases were clear cell (2 with sarcomatoid features), 2 papillary, and 1 chromophobe with histologic fidelity between the primary and metastasis. Of cases with available data, the primaries' ISUP nucleolar grades were 2 (n=2), 3 (n=4), and 4 for the 2 cases with sarcomatoid features. In 8 cases, the bladder RCC undermined overlying urothelium with extensive urothelial denudation, and in 3 cases the RCC was free floating without attachment to the urothelium. The 1 chromophobe RCC metastasized with pagetoid spread to a preexisting urothelial papilloma. PAX8 immunohistochemistry was used to confirm the diagnosis in 2 cases. Three patients have no evidence of disease (7, 9, and 13 mo). Two are alive with disease after chemotherapy (30, 37 mo). Six patients are dead of disease with multiorgan metastases; 4 are dead after therapy (5, 8, 25, 28 mo), and two died without radiation or chemotherapy at 10 and 71 months. Metastatic RCC to the urinary bladder is uncommon, with most cases clear cell RCC. In some cases, evidence supports "drop metastases" as the mechanism of spread and patients have relatively long survival. However, in other cases spread to the bladder is in the setting of metastases to other sites, and these patients tended to die relatively shortly after their bladder metastases.

show abstract

Long-term survival after “drop metastases” of renal cell carcinoma to the bladder

Cited by 21 publications

References 9 publications

Rare synchronous metastases of renal cell carcinoma

Rare synchronous metastases of renal cell carcinoma

Renal cell carcionoma with synchronous metastases to the bladder and lung

Metastatic Renal Cell Carcinoma to the Urinary Bladder

Contact Info

Product

Resources

About